Imugene's milestone in cancer treatment

Imugene (ASX:IMU), a clinical-stage immuno-oncology company, has announced a significant achievement in its Phase 1 MAST trial. A patient with bile tract cancer has maintained a complete response for over two years with their novel cancer-killing virus, VAXINIA. This success has led to an expansion in patient enrolment for the trial.

Imugene's strategic advancements in cancer therapy

Imugene has made notable progress in its Phase 1 MAST trial, with a bile tract cancer patient showing a complete response for over two years using their oncolytic virus, VAXINIA. This has allowed for the expansion of the trial to include more patients. VAXINIA has received both FDA Fast Track and Orphan Drug Designations, facilitating faster approval processes and market exclusivity. A US patent extension for CF33, including VAXINIA, has been granted until 2040, securing its method of composition and use. Imugene is focused on developing innovative immunotherapies to transform cancer treatment, supported by a diverse pipeline of candidates and a team of international experts.

CEO's insights on Imugene's progress

We are pleased with the patent extension and the two-year milestone for the bile tract cancer patient, highlighting the potential of the CF33 oncolytic virus.